title: Feasibility of idiotype vaccination in relapsed B-cell malignancies.
authors.forename: Susana
authors.initials: S
authors.lastname: Inogés
authors.forename: Mercedes
authors.initials: M
authors.lastname: Rodríguez-Calvillo
authors.forename: Ascensión
authors.initials: A
authors.lastname: López-Díaz de Cerio
authors.forename: Natalia
authors.initials: N
authors.lastname: Zabalegui
authors.forename: Javier
authors.initials: J
authors.lastname: Pérez-Calvo
authors.forename: Carlos
authors.initials: C
authors.lastname: Panizo
authors.forename: Milagros
authors.initials: M
authors.lastname: Hernandez
authors.forename: Braulia
authors.initials: B
authors.lastname: Cuesta
authors.forename: Eduardo
authors.initials: E
authors.lastname: Rocha
authors.forename: Maurizio
authors.initials: M
authors.lastname: Bendandi
mesh_terms: D019496:Cancer Vaccines / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D015448:Leukemia, B-Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes